Table 4.

Summary of study outcomes

Study and domain	SWP I	SWP II
QoL	Improved QoL, cognitive functioning, health distress, overall health perceptions and mental health	Improved QoL mental health
Depression and anxiety	Decreased depression and anxiety	Decreased depression
Medication adherence	Increased ARV adherence	Increased ARV adherence among low adherers, increase in emotion-focused coping skills related to adherence, and decrease in number of reasons for missing dose
VL	Increased CB-SE skills related to decreases in VL and AIDS-SE related to increases in CD4 count over time	VL decreased
Sexual risk reduction and domestic violence	N/A	Decreased unprotected sex and increased use of vaginal sexual barriers
Alcohol and drug use	N/A	No changes noted
Nutrition	N/A	Dietary patterns improved for REAP total, sugar, and fat
Physical activity	N/A	Increased walking activity for minutes/day

Note: These outcomes were not assessed in SWP I.

Abbreviations: AIDS-SE, acquired immunodeficiency syndrome self-efficacy; ARV, antiretroviral therapy; CB-SE, cognitive–behavioral self-efficacy; N/A, not applicable; QoL, quality of life; SWP I/II, stress management and relaxation training/expressive-supportive therapy (SMART/EST) Women’s Program – first study/second study; VL, viral load.